Melatonin receptor agonist

Last updated

Melatonin receptor agonist
Drug class
Melatonin.svg
Melatonin, the prototypical melatonin receptor agonist
Class identifiers
UseSleep disorders, depression, ADHD, etc.
ATC code N05CH
Biological target Melatonin receptor
Clinical data
WebMD RxList
External links
MeSH D008550
Legal status
In Wikidata

Melatonin receptor agonists are analogues of melatonin that bind to and activate the melatonin receptor. [1] Agonists of the melatonin receptor have a number of therapeutic applications including treatment of sleep disorders and depression. The discovery and development of melatonin receptor agonists was motivated by the need for more potent analogues than melatonin, with better pharmacokinetics and longer half-lives. Melatonin receptor agonists were developed with the melatonin structure as a model. [1]

Contents

The melatonin receptors are G protein-coupled receptors and are expressed in various tissues of the body. There are two subtypes of the receptor in humans, melatonin receptor 1 (MT1) and melatonin receptor 2 (MT2). [2] Melatonin and melatonin receptor agonists, on market or in clinical trials, all bind to and activate both receptor types. [1] The binding of the agonists to the receptors has been investigated since 1986, yet is still not fully understood. [1] [3] [4] When melatonin receptor agonists bind to and activate their receptors it causes numerous physiological processes. [2] [4] [5] [6]

History

Melatonin timeline to about 2010 Melatonin timeline.jpg
Melatonin timeline to about 2010

In 1917 McCord and Allen discovered melatonin itself. [7] In 1958, Aaron B. Lerner and his colleagues isolated the substance N-acetyl-5-methoxytryptamine and named it melatonin. [1] [7] High-affinity melatonin binding sites were pharmacologically characterized in the bovine brain in 1979. The first melatonergic receptor was cloned from melanophores of Xenopus laevis in 1994. [7] In 1994-1995 the melatonin receptors were characterized and cloned in the human being by Reppert and colleagues. [8]

TIK-301 (PD-6735, LY-156735) has been in phase II clinical trial in the United States (US) since 2002. [1] The FDA granted TIK-301 orphan drug designation in May 2004, to use as a treatment for circadian rhythm sleep disorder in blind individuals without light perception and individuals with tardive dyskinesia. [1] In 2005 ramelteon (Rozerem) was approved in the US indicated for treatment of insomnia, characterized as difficulty with falling asleep, in adults.[ citation needed ] Melatonin in the form of prolonged release (trade name Circadin) was approved in 2007 in Europe (EU) for use as a short-term treatment, in patients 55 years or older, for primary insomnia (poor quality of sleep).[ citation needed ] Products containing melatonin are available as a dietary supplement in the United States[ citation needed ] and Canada. In 2009 agomelatine (Valdoxan, Melitor, Thymanax) was also[ clarification needed ] approved in Europe and is indicated for the treatment of major depressive disorder in adults.[ citation needed ] Tasimelteon completed the phase III clinical trial in the United States for primary insomnia in 2010. [9] The Food and Drug Administration (FDA) granted tasimelteon orphan drug designation status for blind individuals without light perception with non-24-hour sleep–wake disorder in January the same year,[ citation needed ] and final FDA approval for the same purpose was achieved in January 2014 under the trade name Hetlioz. [10]

Melatonin receptors

MT1 melatonin receptor signaling MT1 melatonin receptor signaling.jpg
MT1 melatonin receptor signaling
MT2 melatonin receptor signaling MT2 melatonin receptor signaling.jpg
MT2 melatonin receptor signaling

In humans there are two subtypes of melatonin receptors targeted by melatonin agonists, MT1 and MT2. They are G protein-coupled receptors and are expressed in various tissues of the body, together or singly. [2] MT1 receptors are expressed in many regions of the central nervous system (CNS): suprachiasmatic nucleus (SCN) of the hypothalamus, hippocampus, substantia nigra, cerebellum, central dopaminergic pathways, ventral tegmental area and nucleus accumbens. [2] [5] MT1 is also expressed in the retina, ovary, testis, mammary gland, coronary circulation and aorta, gallbladder, liver, kidney, skin and the immune system. MT2 receptors are expressed mainly in the CNS, also in the lung, cardiac, coronary and aortic tissue, myometrium and granulosa cells, immune cells, duodenum and adipocytes. [2]

Mechanism of action

The binding of melatonin to melatonin receptors activates a few signaling pathways. [1] MT1 receptor activation inhibits the adenylyl cyclase and its inhibition causes a rippling effect of non activation; starting with decreasing formation of cyclic adenosine monophosphate (cAMP), and then progressing to less protein kinase A (PKA) activity, which in turn hinders the phosphorylation of cAMP responsive element-binding protein (CREB binding protein) into P-CREB. [4] MT1 receptors also activate phospholipase C (PLC), affect ion channels and regulate ion flux inside the cell. [1] [2] [4] The binding of melatonin to MT2 receptors inhibits adenylyl cyclase which decreases the formation of cAMP. [4] As well it hinders guanylyl cyclase and therefore the forming of cyclic guanosine monophosphate (cGMP). Binding to MT2 receptors probably affects PLC which increases protein kinase C (PKC) activity. Activation of the receptor can lead to ion flux inside the cell. [1] [4]

When melatonin receptor agonists activate their receptors it causes numerous physiological processes. [2] [4] [5] MT1 and MT2 receptors may be a target for the treatment of circadian and non circadian sleep disorders because of their differences in pharmacology and function within the SCN. The SCN is responsible for maintaining the 24 hour cycle which regulates many different body functions ranging from sleep to immune functions. [11] Melatonin receptors have been identified in the cardiovascular system. Evidence from animal studies points to a dual role of melatonin in the vasculature. [2] Activation of MT1 receptors mediates vasoconstriction and the activation of MT2 receptors mediates vasodilation. Melatonin is involved in regulating immune responses in both human and animals through activation of both MT1 and MT2 receptors. [2] [4] MT1 and MT2 receptors are widespread in the eye and are involved in regulating aqueous humor secretion, which is important for glaucoma, and in phototransduction. This is not a complete list since many of the possible processes need further confirmation. [2]

Drug design and development

Receptors and the structure of melatonin are known. Therefore, researchers started to investigate modulations of the core structure to develop better agonists than melatonin; more potent, with better pharmacokinetics and longer half-life. TIK-301 (Figure 1) is an agonist of the early classes. It is very similar to melatonin and has made it to clinical trials. [1] This led to further research on the molecule, mainly substitution of the aromatic ring. Various modulations showed promising activity, especially the naphthalene ring which is present in agomelatine (Figure 1). [1] [7] Other ring systems have also showed melatonin agonist activity. Amongst them are indane which is present in ramelteon (Figure 1) and the ring system of tasimelteon (Figure 1). [1] [3]

Structure-activity relationship

The general structure of melatonin is the indole ring with methoxy group in position 5 (5-methoxy group) and acylaminoethyl side-chain in position 3. [1] The two side-chains are important for binding to and activating the receptors. [3] The indole ring has been evaluated at all positions by the effect of substitutions as seen in Figure 1. [1] Each position is further explained below: [1]

PositionAbbreviationAction
1R1Possible to substitute with small groups like methyl without little changes in binding affinity. Bulky groups lower binding affinity and intrinsic activity.
2R2Addition of iodine, bromine and phenyl functional groups lead to agonists with higher binding affinity of approximately ten-fold.
3R3The acylaminoethyl side-chain is important, as mentioned before. In this position it is possible to control agonist and antagonist activity.
4R4Often involved in ring closure in melatonin agonists, although this position has been poorly investigated.
5R5The methoxy group is important, as mentioned before. Substitution with halogens, such as chlorine (Cl) and bromine (Br) has shown lower binding affinity. Moving the methoxy group to other positions on the indole ring, e.g. 4, 6 or 7, leads to lower binding affinity.
6R6Substitution leads to lower binding affinity, but this position is important for the pharmacokinetics. The main metabolite in vivo is 6-hydroxymelatonin.
7R7Introduction of groups at this position generally leads to lower binding affinity.
βRβPossible to substitute with small groups like methyl without little changes in binding affinity. Bulkier groups lower binding affinity.
Melatonin SAR structure.svg
SAR
Melatonin structure.svg
Melatonin
Ramelteon structure.svg
Ramelteon
Agomelatine structure.svg
Agomelatine
Tasimelteon structure.svg
Tasimelteon
LY-156,735 structure.svg
TIK-301
Figure 1: Melatonin receptor agonists. The applied colors indicate the mutual properties with the general melatonin receptor agonists pharmacophore.

Binding and pharmacophore

2-Iodomelatonin was synthesized in 1986 and its radioligand, 2-[125I]-melatonin, has been useful in finding cellular targets of melatonin. Though the melatonin receptor was not characterized and cloned in the human being until 1994 it was possible to start carrying out binding studies in various tissues before that time. [1] As mentioned in the structure-activity relationship chapter above, certain groups are important for the activity. The most important groups are the 5-methoxy group and the acylaminoethyl side-chain, because they bind to and activate the receptors. [3] [4] The –NH group of the indole ring is not important for binding and activation. In fact, it is possible to replace the indole with other aromatic ring systems (naphthalene, benzofuran, benzothiazole, indane, tetraline, tetrahydroquinolines). [12] [13] An example of approved drug with naphthalene ring is agomelatine. The aromatic ring and the ethyl side-chain hold the correct distance between those two groups, as the correct distance is the key to good binding and more important than what type of aromatic ring system the analogue contains. Therefore, it is possible to use different ring systems in melatonin receptor analogues, if the distance is right. [1] [3] [4] Furthermore, the aromatic ring can be substituted with different flexible scaffolds, such as phenyl-propilamides, O-phenoxy-ethylamides or N-anilino-ethylamides. [12] The ethylamide chain of these ligands has been thought having a bioactive conformation with said chain projecting outside of the indole plane and it was demonstrated by testing rigidified analogues. [14] Substituents in positions 1 or 2 of the indole scaffold projecting outside of the aromatic cycle plane increase selectivity toward the MT2 receptor, resulting in the most selective melatonin receptor ligands and simultaneously reducing receptor activation. [15] [16]

The melatonin receptors consist of proteins around 40 kDa each. The MT1 receptor encodes 350 amino acids and the MT2 encodes 362 amino acids. The binding of melatonin and its analogues is now understood through X-ray crystal structures published in 2019. [17] The binding space for melatonin and analogues on the MT1 receptor is smaller than on the MT2. [4] [17] Investigations usually focus on two binding pockets, for the two side-chains. The binding pocket of the 5-methoxy group is more investigated than the other pocket. [4] [5] Researchers agree that the oxygen in the group binds to histidine (His) residues in transmembrane 5 (TM5) domain of the receptor with a hydrogen bond; His1955.46 in MT1 and His2085.46 in MT2. [3] [4] Another amino acid, Val192, also participates in the binding of the 5-methoxy group by binding to the methyl portion of the group. [4] His1955.46 has also been proposed as important for receptor activation.

The binding of the N-acetyl group is more complex and less known. The important amino acids in the binding pocket for this group differ between the two receptors. Serines, Ser110 and Ser114, in the TM3 domain seem to be important for binding to the MT1 receptor. However, asparagine 175 (Asn) in the TM4 domain is likely to be important for the MT2 receptor. [4] The aromatic ring system in melatonin and analogues most likely contributes some binding affinity by binding to aromatic rings of the amino acids phenylalanine (Phe) and tryptophan (Trp) in the receptor. The bonds that form are van der Waals interactions. [3] The N-acetyl binding and binding pocket, binding of the ring system and important domains are somewhat known and need further investigation. [1] [3] [4]

In past years, mutagenesis of residues involved in the binding site was not fully successful in the determination of the polar key contacts [13] established by the methoxy group and the ethyl-amide side chain. Asn162/1754.60 and the Gln181/194, belonging to the ECL2, bind the methoxy and the ethyl-amide groups, respectively. The importance of His195/2085.46 could be related to the receptor activation, since cryo-electron microscopy structures of the ternary complexes of the receptor show that the residues enters the binding site, near the "toogle-switch" residue Trp6.48. [6]

Carbamate insecticides target human melatonin receptors. [18] Despite its structural similarities with melatonin, serotonin is not able to bind melatonin receptor due to the polar first amine group and the lack of an aspartate in position 3.32 within melatonin receptor orthosteric site.

Current status

There are three melatonin agonists on the market today (February 2014); ramelteon (Rozerem), agomelatine (Valdoxan, Melitor, Thymanax) and tasimelteon (Hetlioz). Ramelteon was developed by Takeda Pharmaceutical Company and approved in the United States in 2005. Agomelatine was developed by the pharmaceutical company Servier and approved in Europe 2009. Tasimelteon was developed by Vanda Pharmaceuticals and completed the phase III trial in 2010. It was approved by the FDA on January 31, 2014, for the treatment of non-24-hour sleep–wake disorder in totally blind individuals. [10]

One melatonin agonist has received orphan drug designation and is going through clinical trials in the United States: TIK-301. Originally TIK-301 was developed by Eli Lilly and Company and called LY-156,735, it wasn't until July 2007 that Tikvah Pharmaceuticals took over the development and named it TIK-301. It is now in phase II trials and has been since 2002. [1] [19] [ unreliable source? ] In July 2010 in Europe, prolonged-release melatonin (Circadin, Neurim Pharmaceuticals) was approved for use for 13 weeks for insomnia patients over 55 years old. [20] Additionally, Neurim Pharmaceuticals reported the results of a positive phase II trial of its investigational compound piromelatine (Neu-P11) in February 2013. [21]

No antagonists or selective ligands are currently reported in clinical studies.

Several characteristics of approved receptor agonists and orphan drug agonists [1] [8] [22] [23]
CircadinRamelteonAgomelatineTasimelteonTIK-301
Binding affinity—MT1: Ki = 0.014 nM
MT2: Ki = 0.045 nM		MT1: Ki = 0.062 nM
MT2: Ki = 0.268 nM
5-HT2C: IC50 = 270 nM*		MT1: Ki = 0.35 nM
MT2: Ki = 0.17 nM		MT1: Ki = 0.081nM
MT2: Ki = 0.042 nM
Bioavailability15%< 2%< 5%not determined in humans—
Half-life40–50 min
3.5–4 h (terminal)		1–2 h1–2 h0.9–1.7 h
0.8–5.9 h (terminal)		—
Protein binding60%82%95%89–90%—
Volume of distribution—73.6 L35 L56–126 L—
CompanyNeurim PharmaceuticalsTakeda Pharmaceutical CompanyServierVanda PharmaceuticalsTikvah Pharmaceuticals
*Serotonin antagonist.

Related Research Articles

<span class="mw-page-title-main">Melatonin</span> Hormone released by the pineal gland

Melatonin, an indoleamine, is a natural compound produced by various organisms, including bacteria and eukaryotes. Its discovery in 1958 by Aaron B. Lerner and colleagues stemmed from the isolation of a substance from the pineal gland of cows that could induce skin lightening in common frogs. This compound was later identified as a hormone secreted in the brain during the night, playing a crucial role in regulating the sleep-wake cycle, also known as the circadian rhythm, in vertebrates.

<span class="mw-page-title-main">Agomelatine</span> Atypical antidepressant classified primarily as a melatonin receptor agonist

Agomelatine, sold under the brand names Valdoxan and Thymanax, among others, is an atypical antidepressant most commonly used to treat major depressive disorder and generalized anxiety disorder. One review found that it is as effective as other antidepressants with similar discontinuation rates overall but fewer discontinuations due to side effects. Another review also found it was similarly effective to many other antidepressants.

<span class="mw-page-title-main">Ramelteon</span> Hypnotic medication

Ramelteon, sold under the brand name Rozerem among others, is a melatonin agonist medication which is used in the treatment of insomnia. It is indicated specifically for the treatment of insomnia characterized by difficulties with sleep onset. It reduces the time taken to fall asleep, but the degree of clinical benefit is small. The medication is approved for long-term use. Ramelteon is taken by mouth.

Melatonin receptors are G protein-coupled receptors (GPCR) which bind melatonin. Three types of melatonin receptors have been cloned. The MT1 (or Mel1A or MTNR1A) and MT2 (or Mel1B or MTNR1B) receptor subtypes are present in humans and other mammals, while an additional melatonin receptor subtype MT3 (or Mel1C or MTNR1C) has been identified in amphibia and birds. The receptors are crucial in the signal cascade of melatonin. In the field of chronobiology, melatonin has been found to be a key player in the synchrony of biological clocks. Melatonin secretion by the pineal gland has circadian rhythmicity regulated by the suprachiasmatic nucleus (SCN) found in the brain. The SCN functions as the timing regulator for melatonin; melatonin then follows a feedback loop to decrease SCN neuronal firing. The receptors MT1 and MT2 control this process. Melatonin receptors are found throughout the body in places such as the brain, the retina of the eye, the cardiovascular system, the liver and gallbladder, the colon, the skin, the kidneys, and many others. In 2019, X-ray crystal and cryo-EM structures of MT1 and MT2 were reported.

<i>N</i>-Acetylserotonin Chemical compound

N-Acetylserotonin (NAS), also known as normelatonin, is a naturally occurring chemical intermediate in the endogenous production of melatonin from serotonin. It also has biological activity in its own right, including acting as a melatonin receptor agonist, an agonist of the TrkB, and having antioxidant effects.

Cutamesine (SA 4503) is a synthetic sigma receptor agonist which is selective for the σ1 receptor, a chaperone protein mainly found in the endoplasmic reticulum of cells in the central nervous system. These σ1 receptors play a key role in the modulation of Ca2+ release and apoptosis. Cutamesine's activation of the σ1 receptor is tied to a variety of physiological phenomena in the CNS, including activation of dopamine-releasing neurons and repression of the MAPK/ERK pathway.

The orexin receptor (also referred to as the hypocretin receptor) is a G-protein-coupled receptor that binds the neuropeptide orexin. There are two variants, OX1 and OX2, each encoded by a different gene (HCRTR1, HCRTR2).

<span class="mw-page-title-main">Melatonin receptor 1B</span> Protein-coding gene in the species Homo sapiens

Melatonin receptor 1B, also known as MTNR1B, is a protein that in humans is encoded by the MTNR1B gene.

A cannabinoid receptor antagonist, also known simply as a cannabinoid antagonist or as an anticannabinoid, is a type of cannabinoidergic drug that binds to cannabinoid receptors (CBR) and prevents their activation by endocannabinoids. They include antagonists, inverse agonists, and antibodies of CBRs. The discovery of the endocannabinoid system led to the development of CB1 receptor antagonists. The first CBR inverse agonist, rimonabant, was described in 1994. Rimonabant blocks the CB1 receptor selectively and has been shown to decrease food intake and regulate body-weight gain. The prevalence of obesity worldwide is increasing dramatically and has a great impact on public health. The lack of efficient and well-tolerated drugs to cure obesity has led to an increased interest in research and development of CBR antagonists. Cannabidiol (CBD), a naturally occurring cannabinoid and a non-competitive CB1/CB2 receptor antagonist, as well as Δ9-tetrahydrocannabivarin (THCV), a naturally occurring cannabinoid, modulate the effects of THC via direct blockade of cannabinoid CB1 receptors, thus behaving like first-generation CB1 receptor inverse agonists, such as rimonabant. CBD is a very low-affinity CB1 ligand, that can nevertheless affect CB1 receptor activity in vivo in an indirect manner, while THCV is a high-affinity CB1 receptor ligand and potent antagonist in vitro and yet only occasionally produces effects in vivo resulting from CB1 receptor antagonism. THCV has also high affinity for CB2 receptors and signals as a partial agonist, differing from both CBD and rimonabant.

<span class="mw-page-title-main">Tasimelteon</span> Wakefulness medication

Tasimelteon, sold under the brand name Hetlioz, is a medication approved by the U.S. Food and Drug Administration (FDA) in January 2014, for the treatment of non-24-hour sleep–wake disorder. In June 2014, the European Medicines Agency (EMA) accepted an EU filing application for tasimelteon and in July 2015, the drug was approved in the European Union for the treatment of non-24-hour sleep-wake rhythm disorder in totally blind adults, but not in the case of non-24 in sighted people.

The first antiandrogen was discovered in the 1960s. Antiandrogens antagonise the androgen receptor (AR) and thereby block the biological effects of testosterone and dihydrotestosterone (DHT). Antiandrogens are important for men with hormonally responsive diseases like prostate cancer, benign prostatic hyperplasia (BHP), acne, seborrhea, hirsutism and androgen alopecia. Antiandrogens are mainly used for the treatment of prostate diseases. Research from 2010 suggests that ARs could be linked to the disease progression of triple-negative breast cancer and salivary duct carcinoma and that antiandrogens can potentially be used to treat it.

<span class="mw-page-title-main">Substituted tryptamine</span> Class of indoles

Substituted tryptamines, or serotonin analogues, are organic compounds which may be thought of as being derived from tryptamine itself. The molecular structures of all tryptamines contain an indole ring, joined to an amino (NH2) group via an ethyl (−CH2–CH2−) sidechain. In substituted tryptamines, the indole ring, sidechain, and/or amino group are modified by substituting another group for one of the hydrogen (H) atoms.

<span class="mw-page-title-main">TIK-301</span> Chemical compound

TIK-301 (LY-156735) is an agonist for the melatonin receptors MT1 and MT2 that is under development for the treatment of insomnia and other sleep disorders. Its agonist action on MT1 and MT2 receptors in the suprachiasmatic nucleus in the brain enables its action as a chronobiotic. It is in the same class of melatonin receptor agonists as ramelteon and tasimelteon.

<span class="mw-page-title-main">Piromelatine</span> Chemical compound

Piromelatine (Neu-P11) is a multimodal sleep drug under development by Neurim Pharmaceuticals. It is an agonist at melatonin MT1/MT2 and serotonin 5-HT1A/5-HT1D receptors. Neurim is conducting a phase II randomized, placebo controlled trial of cognitive and sleep effects in Alzheimer's disease.

Margarita L. Dubocovich, Ph.D., FACNP, FASPET is an Argentine neuropharmacologist currently a SUNY Distinguished Professor at University of Buffalo, State University of New York.

<span class="mw-page-title-main">Willardiine</span> Chemical compound

Willardiine (correctly spelled with two successive i's) or (S)-1-(2-amino-2-carboxyethyl)pyrimidine-2,4-dione is a chemical compound that occurs naturally in the seeds of Mariosousa willardiana and Acacia sensu lato. The seedlings of these plants contain enzymes capable of complex chemical substitutions that result in the formation of free amino acids (See:#Synthesis). Willardiine is frequently studied for its function in higher level plants. Additionally, many derivates of willardiine are researched for their potential in pharmaceutical development. Willardiine was first discovered in 1959 by R. Gmelin, when he isolated several free, non-protein amino acids from Acacia willardiana (another name for Mariosousa willardiana) when he was studying how these families of plants synthesize uracilyalanines. A related compound, Isowillardiine, was concurrently isolated by a different group, and it was discovered that the two compounds had different structural and functional properties. Subsequent research on willardiine has focused on the functional significance of different substitutions at the nitrogen group and the development of analogs of willardiine with different pharmacokinetic properties. In general, Willardiine is the one of the first compounds studied in which slight changes to molecular structure result in compounds with significantly different pharmacokinetic properties.

<span class="mw-page-title-main">2-Iodomelatonin</span> Chemical compound

2-Iodomelatonin is a melatonin analog used as a radiolabelled ligand for the melatonin receptors, MT1, MT2, and MT3. It acts as a full agonist at both MT1 and MT2 receptors.

<span class="mw-page-title-main">Melatonin as a medication and supplement</span> Supplement and medication used to treat sleep disorders

Melatonin is a naturally occurring hormone produced in the brain that is also used as a dietary supplement and medication. As a hormone, melatonin is released by the pineal gland and is involved in sleep–wake cycles. As a supplement, it is often used for the attempted short-term treatment of disrupted sleep patterns, such as from jet lag or shift work, and is typically taken orally. There is evidence of its benefit for this use, but is not strong. A 2017 review found that sleep onset occurred six minutes faster with use, but found no change in total time asleep.

Gabriella Gobbi is an Italo-Canadian psychiatrist and neuroscientist whose research explores novel treatments for mental health disorders. Gobbi is a professor at McGill University's Department of Psychiatry and a Canada Research Chair in Therapeutics for Mental Health.

<span class="mw-page-title-main">Somnifacient</span> Class of medications that induce sleep

Somnifacient, also known as sedatives or sleeping pills, is a class of medications that induces sleep. It is mainly used for treatment of insomnia. Examples of somnifacients include benzodiazepines, barbiturates and antihistamines.

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Rivara S, Mor M, Bedini A, Spadoni G, Tarzia G (2008). "Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders". Current Topics in Medicinal Chemistry. 8 (11): 954–968. doi:10.2174/156802608784936719. PMID   18673165.
  2. 1 2 3 4 5 6 7 8 9 10 Pandi-Perumal SR, Trakht I, Srinivasan V, Spence DW, Maestroni GJ, Zisapel N, et al. (July 2008). "Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways". Progress in Neurobiology. 85 (3): 335–353. doi:10.1016/j.pneurobio.2008.04.001. PMID   18571301. S2CID   42549910.
  3. 1 2 3 4 5 6 7 8 Sugden D, Davidson K, Hough KA, Teh MT (October 2004). "Melatonin, melatonin receptors and melanophores: a moving story". Pigment Cell Research. 17 (5): 454–460. doi: 10.1111/j.1600-0749.2004.00185.x . PMID   15357831.
  4. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Dubocovich ML, Delagrange P, Krause DN, Sugden D, Cardinali DP, Olcese J (September 2010). "International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors". Pharmacological Reviews. 62 (3): 343–380. doi:10.1124/pr.110.002832. PMC   2964901 . PMID   20605968.
  5. 1 2 3 4 Witt-Enderby PA, Bennett J, Jarzynka MJ, Firestine S, Melan MA (April 2003). "Melatonin receptors and their regulation: biochemical and structural mechanisms". Life Sciences. 72 (20): 2183–2198. doi:10.1016/S0024-3205(03)00098-5. PMID   12628439.
  6. 1 2 Wang Q, Lu Q, Guo Q, Teng M, Gong Q, Li X, et al. (January 2022). "Structural basis of the ligand binding and signaling mechanism of melatonin receptors". Nature Communications. 13 (1): 454. Bibcode:2022NatCo..13..454W. doi: 10.1038/s41467-022-28111-3 . PMC   8786939 . PMID   35075127.
  7. 1 2 3 4 de Bodinat C, Guardiola-Lemaitre B, Mocaër E, Renard P, Muñoz C, Millan MJ (August 2010). "Agomelatine, the first melatonergic antidepressant: discovery, characterization and development". Nature Reviews. Drug Discovery. 9 (8): 628–642. doi:10.1038/nrd3140. PMID   20577266. S2CID   54524999.
  8. 1 2 Ferguson SA, Rajaratnam SM, Dawson D (February 2010). "Melatonin agonists and insomnia". Expert Review of Neurotherapeutics. 10 (2): 305–318. doi:10.1586/ern.10.1. PMID   20136385. S2CID   25430719.
  9. ↑ Rajaratnam SM, Cohen DA, Rogers NL (2009). "Melatonin and Melatonin Analogues". Sleep Medicine Clinics. 4 (2): 179–93. doi:10.1016/j.jsmc.2009.02.007.
  10. 1 2 "FDA approves Hetlioz: first treatment for non-24 hour sleep-wake disorder in blind individuals" (Press release). FDA. January 31, 2014. Archived from the original on February 2, 2014.
  11. ↑ Dubocovich ML (December 2007). "Melatonin receptors: role on sleep and circadian rhythm regulation". Sleep Medicine. 8 (Suppl 3): 34–42. doi:10.1016/j.sleep.2007.10.007. PMID   18032103.
  12. 1 2 Boutin JA, Witt-Enderby PA, Sotriffer C, Zlotos DP (October 2020). "Melatonin receptor ligands: A pharmaco-chemical perspective". Journal of Pineal Research. 69 (3): e12672. doi: 10.1111/jpi.12672 . PMID   32531076.
  13. 1 2 Elisi GM, Scalvini L, Lodola A, Bedini A, Spadoni G, Rivara S (April 2022). "In silico drug discovery of melatonin receptor ligands with therapeutic potential". Expert Opinion on Drug Discovery. 17 (4): 343–354. doi:10.1080/17460441.2022.2043846. PMID   35255751. S2CID   247295193.
  14. ↑ Rivara S, Diamantini G, Di Giacomo B, Lamba D, Gatti G, Lucini V, et al. (May 2006). "Reassessing the melatonin pharmacophore--enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue". Bioorganic & Medicinal Chemistry. 14 (10): 3383–3391. doi:10.1016/j.bmc.2005.12.053. PMID   16431121.
  15. ↑ Rivara S, Mor M, Silva C, Zuliani V, Vacondio F, Spadoni G, et al. (April 2003). "Three-dimensional quantitative structure-activity relationship studies on selected MT1 and MT2 melatonin receptor ligands: requirements for subtype selectivity and intrinsic activity modulation". Journal of Medicinal Chemistry. 46 (8): 1429–1439. doi:10.1021/jm020982d. PMID   12672242.
  16. ↑ Mari M, Elisi GM, Bedini A, Lucarini S, Retini M, Lucini V, et al. (December 2022). "2-Arylmelatonin analogues: Probing the 2-phenyl binding pocket of melatonin MT1 and MT2 receptors". European Journal of Medicinal Chemistry. 243: 114762. doi:10.1016/j.ejmech.2022.114762. hdl: 11576/2704150 . PMID   36150258. S2CID   252295726.
  17. 1 2 Stauch B, Johansson LC, Cherezov V (April 2020). "Structural insights into melatonin receptors". The FEBS Journal. 287 (8): 1496–1510. doi:10.1111/febs.15128. PMC   7174090 . PMID   31693784.
  18. ↑ Popovska-Gorevski M, Dubocovich ML, Rajnarayanan RV (February 2017). "Carbamate Insecticides Target Human Melatonin Receptors". Chemical Research in Toxicology. 30 (2): 574–582. doi:10.1021/acs.chemrestox.6b00301. PMC   5318275 . PMID   28027439.
  19. ↑ "Future Treatments for Depression, Anxiety, Sleep Disorders, Psychosis, and ADHD". Neurotransmitter.net. 2011-06-17. Retrieved 2012-02-10.
  20. ↑ "Circadin approved in the EU for treatment of Primary Insomnia in patients aged 55 or over for up to 3 months" (Press release). Neurim Pharmaceuticals. July 5, 2010. Retrieved February 19, 2020.
  21. ↑ "Neurim Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of Piromelatine for the Treatment of Insomnia" (Press release). Neurim Pharmaceuticals. February 18, 2013. Retrieved February 19, 2020.
  22. ↑ "Highlights of prescribing information for Hetlioz" (PDF).
  23. ↑ "Tasimelteon Advisory Committee Meeting Briefing Materials" (PDF). Vanda Pharmaceuticals. November 2013. Archived from the original (PDF) on November 25, 2013.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.